Abstract
Immunotherapy is distinct from traditional chemotherapy in that it acts on immune cells rather than cancer cells themselves. Monoclonal antibodies targeting immune checkpoints on T cells - CTLA-4 and PD-1 - and PD-L1 on the cells of immune microenvironment are now approved for clinical use in several solid tumors and hematological malignancies. This article provides a general overview of the use of checkpoint inhibitors in hematologic malignancies with a special focus in acute myeloid leukemia.
Keywords:
CTLA-4; PD-1; PD-L1; acute myeloid leukemia; checkpoint inhibitors.
© 2019 British Society for Haematology and John Wiley & Sons Ltd.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Agents, Immunological / therapeutic use*
-
B7-H1 Antigen / antagonists & inhibitors
-
B7-H1 Antigen / immunology
-
CTLA-4 Antigen / antagonists & inhibitors
-
CTLA-4 Antigen / immunology
-
Hematologic Neoplasms / immunology
-
Hematologic Neoplasms / pathology
-
Hematologic Neoplasms / therapy*
-
Humans
-
Immunotherapy*
-
Leukemia, Myeloid, Acute / immunology
-
Leukemia, Myeloid, Acute / pathology
-
Leukemia, Myeloid, Acute / therapy*
-
Neoplasm Proteins / antagonists & inhibitors
-
Neoplasm Proteins / immunology
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Programmed Cell Death 1 Receptor / immunology
Substances
-
Antineoplastic Agents, Immunological
-
B7-H1 Antigen
-
CD274 protein, human
-
CTLA-4 Antigen
-
CTLA4 protein, human
-
Neoplasm Proteins
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor